Rosuvastatin is a potent competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the statin class of cholesterol-lowering drugs. Rosuvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans. Shown to have anti-inflammatory, antioxidant, antithrombotic and insulin sensitizing properties. Identified as a potential inhibitor of SARS-CoV-2, responsible for COVID-19.